PEG-MGF
PEGylated Mechano Growth Factor
Mechanism of Action
PEGylated form of the C-terminal peptide encoded by the Ec/MGF splice variant of the IGF-1 gene. The native splice variant is transiently upregulated in muscle after mechanical damage and activates quiescent satellite (stem) cells to re-enter the cell cycle; PEGylation is intended to slow degradation and extend that signaling window, though this specific construct has not been directly studied in peer-reviewed literature.
Key Benefits
- Satellite cell activation and proliferation (native MGF, preclinical)
- Extended signaling window vs native MGF (theoretical, via PEGylation)
- Localized muscle repair support
Dosing Protocol
Compliance-relevant caveat: essentially all peer-reviewed MGF literature covers the native, non-PEGylated splice variant studied in animal/cell models (Goldspink group). PEG-MGF as sold is a research-market construct — treat dosing/half-life figures as community convention, not literature-derived.
Ideal Candidates
Advanced users targeting a specific trained muscle group post-injury or post-training; the evidence gap should be weighed heavily.
Side Effects & Safety
Injection site reactions; theoretical growth-factor risks shared with the broader IGF-1 axis; human safety profile unpublished.
Regulatory Status
RestrictedResearch compound only. No 503A bulks list. No published human or PEGylated-construct trials — extrapolated from native MGF splice-variant biology; treat potency/duration claims as unverified.
Evidence & Citations
- Matheny RW, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151(3):865-75.
- Dai Z, Wu F, Yeung EW, Li Y. IGF-IEc expression, regulation and biological function in different tissues. Growth Horm IGF Res. 2010;20(4):275-81.
- Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409-18.
Frequently asked
What is PEG-MGF?+
PEG-MGF (PEGylated Mechano Growth Factor) is a peptide studied for igf-1 splice variant and extended half-life. PEGylated form of the C-terminal peptide encoded by the Ec/MGF splice variant of the IGF-1 gene. The native splice variant is transiently upregulated in muscle after mechanical damage and activates quiescent satellite (stem) cells to re-enter the cell cycle; PEGylation is intended to slow degradation and extend that signaling window, though this specific construct has not been directly studied in peer-reviewed literature.
What is the dosing protocol for PEG-MGF?+
Literature commonly references 200 mcg/wk (low) to 400–600 mcg/wk (split 2x/wk) (maintenance) via SubQ / IM (near trained muscle), on a 4–6 weeks cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of PEG-MGF?+
Research compound only. No 503A bulks list. No published human or PEGylated-construct trials — extrapolated from native MGF splice-variant biology; treat potency/duration claims as unverified.
Where can I access PEG-MGF?+
Research-grade PEG-MGF is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.